Diabetes Treatment, Part 2: Oral Agents for Glycemic Management

@article{Fowler2007DiabetesTP,
  title={Diabetes Treatment, Part 2: Oral Agents for Glycemic Management},
  author={Michael J. Fowler},
  journal={Clinical Diabetes},
  year={2007},
  volume={25},
  pages={131-134}
}
  • M. Fowler
  • Published 1 October 2007
  • Medicine
  • Clinical Diabetes
T he epidemic of type 2 diabetes in the United States and the rest of the world continues to grow rapidly; as many as 20 million people in the United States may have the disease.1 The vast majority of people with diabetes have type 2 diabetes, caused by a relative insulin deficiency superimposed on a background of insulin resistance.2 Most patients begin treatment with diet and exercise or incorporate them into their treatment regimen, but, unfortunately, most patients are unsuccessful in… 
Drug Resistance in Diabetes
TLDR
This chapter gives the knowledge about diabetes mechanism of drug resistance, classification, pathophysiology and its management and further research is needed to be done in order to prevent the world from this widespread disease.
CURRENT TREATMENTS FOR TYPE 2 DIABETES, THEIR SIDE EFFECTS AND POSSIBLE COMPLEMENTARY TREATMENTS
TLDR
To combat the side effects of these drugs, complementary treatments may be found as a preventive measure and more promising in the management of disease phenotypes in these patients, which may include physical exercise, dietary supplements and Nutraceuticals.
THE SAFETY OF TRIPLE THERAPY WITH ORAL ANTIDIABETICS VERSUS INSULIN IN TYPE 2 DIABETES
TLDR
A patient treated with three oral drugs is subjected to an additive risk of adverse events and drug interaction compared with insulin therapy.
Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus
TLDR
Patient initial level of glycemic control was associated with changes in treatment patterns in the 2 years post initiation on an OAD, with patients with moderate or poor control more likely to switch or augment their ITT therapy, compared to individuals with good control.
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
TLDR
Oral alogliptin as monotherapy or in combination with other oral antihyperglycaemic agents or insulin therapy improved glycaemic control and was generally well tolerated in adult patients with inadequately controlled type 2 diabetes, including elderly patients.
EARLY AGGRESSIVE TREATMENT: METFORMIN-VOGLIBOSE COMBINATION THERAPY VS METFORMIN MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENT
Diabetes has rapidly gained the status of being a pandemic. Adequate treatment of diabetes mellitus is very challenging. Numbers of drugs, with different mechanism of action, catering the needs of
Supplements for Diabetes Mellitus: A Review of the Literature
TLDR
This review will focus on the safety and efficacy data surrounding nicotinamide, ginseng, fenugreek, vitamin D, chromium, and cinnamon, which are commonly listed in general circulation periodicals with claims to improve blood sugar management.
Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications
TLDR
Individualized treatment in T2DM patients with CVDs can be supported through a better understanding of the association between glycemic control and CV profiles in T1DM patients.
Experiences of People With Type 2 Diabetes Using Flexible Intensive Insulin Therapy: A Pilot Study
TLDR
This pilot study explored the experiences of persons with type 2 diabetes who were new users of FIIT, and study outcomes suggest FIIT is safe and effective in this population.
Adverse Effects of Oral Hypoglycemic Agents and Adherence to them among Patients with Type 2 Diabetes Mellitus in Nepal
TLDR
The incidence of adverse effects was high with hypoglycemia occurring in 49.7% of the cases, though only one-third of them recognized it to be due to hyp glucosecemia, in the patients with Type 2 Diabetes Mellitus.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
TLDR
The development of new classes of blood glucose–lowering medications to supplement the older therapies, such as lifestyle-directed interventions, insulin, sulfonylureas, and metformin, has increased the treatment options for type 2 diabetes.
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
TLDR
Metformin monotherapy and combination therapy with metformin and sulfonylurea are well tolerated and improve glycemic control and lipid concentrations in patients with NIDDM whose diabetes is poorly controlled with diet or sulfonyLurea therapy alone.
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
TLDR
Metformin acts primarily by decreasing hepatic glucose output, largely by inhibiting gluconeogenesis, and also seems to induce weight loss, preferentially involving adipose tissue.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
TLDR
This study suggests that treating IGT patients with acarbose is associated with a significant reduction in the risk of cardiovascular disease and hypertension.
Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.
TLDR
Once- or twice- daily extended-release metformin was as safe and effective as twice-daily immediate-release meetformin and provided continued glycemic control for up to 24 weeks of treatment.
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
TLDR
This revision of the consensus algorithm for the medical management of type 2 diabetes focuses on the new classes of medications that now have more clinical data and experience and addresses safety issues surrounding the thiazolidinediones.
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
TLDR
Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.
Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.
TLDR
Administration of GLP-1 along with ingestion of a meal augments insulin secretion in humans by a dose-dependent potentiation of the dose-response relationship between plasma glucose and insulin secretion.
...
1
2
3
...